Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2024, Vol. 56 ›› Issue (4): 624-630. doi: 10.19723/j.issn.1671-167X.2024.04.013

Previous Articles     Next Articles

Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus

Shuai LIU,Lei LIU,Zhuo LIU,Fan ZHANG,Lulin MA,Xiaojun TIAN,Xiaofei HOU,Guoliang WANG,Lei ZHAO,Shudong ZHANG*()   

  1. Department of Urology, Peking University Third Hospital, Beijing 100191, China
  • Received:2024-03-16 Online:2024-08-18 Published:2024-07-23
  • Contact: Shudong ZHANG E-mail:zhangshudong@bjmu.edu.cn
  • Supported by:
    the National Natural Science Foundation of China(82273389)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To analyze the clinicopathological features, prognostic value and surgical treatment experience in patients with adrenocortical carcinoma with venous tumor thrombus. Methods: We collected relevant data of the patients with adrenocortical carcinoma who had undergone surgery in Peking University Third Hospital from 2018 to 2023. The patients were divided into venous tumor thrombus group and non-tumor thrombus group. The Wilcoxon rank sum test was used to compare the quantitative variables. The chi-squared test and Fisher's exact test were used to compare the categorical variables. The Kaplan-Meier method was used to estimate the survival rate. Results: A total of 27 patients with adrenocortical carcinoma were included, of whom 11 cases (40.7%) had venous tumor thrombus. In the patients with venous tumor thrombus, 8 patients were female and 3 were male. The median age was 49 (36, 58) years. The median body mass index was 26.0 (24.1, 30.4) kg/m2. Seven patients presented with symptoms at their initial visit. Six patients had a history of hypertension. Elevated levels of cortisol were observed in 2 cases. Three tumors were found on the left side, while 8 were found on the right side. Median tumor diameter was 9.4 (6.5, 12.5) cm. On the left, there was a case of tumor thrombus limited to the central vein of the left adrenal gland without invasion into the left renal vein, and two cases of tumor thrombus growth extending into the inferior vena cava below the liver. One case of tumor thrombus on the right adrenal central vein did not invade the inferior vena cava. Four cases of tumor thrombus invaded the inferior vena cava below the liver and three cases extended to the posterior of the liver. Ten patients were in European Network for the Study of Adrenal Tumors (ENSAT) stage Ⅲ and one was in ENSAT stage Ⅳ. Open surgery was performed in 6 cases, laparoscopic surgery alone in 4 cases and robot-assisted laparoscopic surgery in 1 case. Two patients underwent ipsilateral kidney resection. Median operative time was 332 (261, 440) min. Median intraoperative bleeding was 900 (700, 2 200) mL. Median hospital stay was 9 (5, 10) days. Median survival time for the patients with tumor thrombus was 24.0 months and median time to recurrence was 7.0 months. The median survival and recurrence time of 16 patients without tumor thrombus were not reached. The patients with tumor thrombus had worse 3-year overall survival (OS) rate (40.9% vs. 71.4%; Log-rank, P=0.038) and 2-year recurrence-free survival (RFS) (9.1% vs.53.7%; Log-rank, P=0.015) rates compared with the patients with non-tumor thrombus. Conclusion: Patients with adrenocortical carcinoma with venous tumor thrombus have poor prognosis. Different adrenal tumor resections and venous tumor thrombus removal procedures based on different tumor thrombus locations are safe and effective in treating this disease.

Key words: Adrenocortical carcinoma, Tumor thrombus, Clinicopathological features, Prognosis

CLC Number: 

  • R699.3

Table 1

Clinical characteristics of ACC with or without tumor thrombus"

Feature With tumor thrombus (n=11) Without tumor thrombus (n=16) P value
Age/years 49 (36, 58) 48 (37, 62) 0.8
Female 8 (72.7) 7 (56.3) 0.4
BMI/(kg/m2) 26.0 (24.1, 30.4) 25.1 (23.3, 27.6) 0.3
Clinical symptoms 0.3
  No 4 (36.4) 11 (68.8)
  Local symptoms 5 (45.5) 3 (18.8)
  Systemic symptoms 2 (18.2) 2 (12.5)
Hypercortisolism 2 (18.2) 2 (12.5) 1.0
Hypertension 6 (54.5) 6 (37.5) 0.5
Side 0.5
  Left 3 (27.3) 7 (43.8)
  Right 8 (72.7) 8 (50.5)
  Bilateral 0 1 (6.3)
Tumor size/cm 9.4 (6.5, 12.5) 10.5 (6.1, 13.0) 1.0
ENSAT stage 0.1
  Ⅰ 0 2 (12.5)
  Ⅱ 0 4 (25.0)
  Ⅲ 10 (90.9) 9 (56.3)
  Ⅳ 1 (9.1) 1 (6.3)
pN1 1 (9.1) 2 (12.5) 1.0
M1 1 (9.1) 1 (6.3) 1.0
Thrombus length/cm 3.0 (1.6, 4.0)
Mayo grade
  0 2 (18.2)
  Ⅰ 2 (18.2)
  Ⅱ 6 (54.5)
  Ⅲ 1 (9.1)
PUTH-RT grading system
  1a 2 (18.2)
  2 6 (54.5)
  3 3 (27.3)
Operative time/min 332.0 (261.0, 440.0) 223.5 (137.8, 308.5) 0.08
Estimated blood loss/mL 900 (700, 2 200) 450 (20, 1 200) 0.09
Patients receiving transfusion 7 (63.6) 8 (50.0) 0.7
Postoperative hospital stay/d 9 (5, 10) 8 (6, 12) 0.9
Postoperative complication 4 (36.4) 4 (25.0) 0.7

Table 2

Clinical and pathological characteristics of all 11 patients with ACC with tumor thrombus"

Patient PUTH-RT grade Mayo grade Age/years Gender BMI/(kg/m2) Hypertension Symptoms Side Diameter/cm ENSAT stage cT stage cN stage cM stage Thrombus length/cm
1 3 Ⅲ 31 F 30.4 No Local R 15.0 Ⅲ T3 N0 M0 5.0
2 2 Ⅰ 58 M 24.1 Yes No R 9.4 Ⅲ T3 N0 M0 3.0
3 2 Ⅱ 56 F 36.2 Yes No R 6.5 Ⅲ T3 N0 M0 4.0
4 2 Ⅱ 49 F 21.5 No Local L 12.2 Ⅲ T4 N0 M0 4.0
5 2 Ⅱ 54 F 26.0 No No R 7.1 Ⅲ T3 N0 M0 3.3
6 3 Ⅱ 69 F 23.1 Yes Systemic R 12.5 Ⅳ T3 N1 M1 3.0
7 1a 0 71 F 26.9 Yes No R 4.5 Ⅲ T3 N0 M0 0.5
8 1a 0 39 M 24.9 No Local L 12.0 Ⅲ T3 N0 M0 0.8
9 2 Ⅱ 23 F 27.7 No Local L 16.3 Ⅲ T4 N0 M0 2.8
10 3 Ⅱ 36 M 24.5 Yes Local R 8.3 Ⅲ T3 N0 M0 2.5
11 2 Ⅰ 49 F 35.9 Yes Systemic R 5.5 Ⅲ T3 N0 M0 1.6

Table 3

Operation and prognosis data of patients with adrenocortical carcinoma with tumor thrombus"

Patient Operation approach Operative time/min Blood loss/mL RCS transfusion/mL LN resection Hospital stay/d Complication Follow-up/months Status Recurrence
1 Open 504 3 500 3 200 No 9 Anemia 14.0 Dead Liver, lung, retroperitoneal
2 Laparoscopic 193 200 0 No 5 12.0 Dead Liver, lung
3 Laparoscopic 335 800 400 No 8 9.0 Dead Liver, lung, retroperitoneal
4 Open 440 2 000 1 600 Yes 9 20.0 Dead Diaphragmatic, lymph node
5 Laparoscopic 261 900 0 No 5 11.0 Dead Liver, lung, retroperitoneal
6 Open 355 3 500 2 800 Yes 10 9.0 Dead Liver
7 Laparoscopic 71 10 0 No 3 24.0 Dead Liver, lung
8 Robot 332 700 0 No 12 Ascites 32.0 Alive
9 Open 477 2 200 1 600 Yes 13 Anemia 19.0 Dead Lung
10 Open 322 1 500 800 No 10 Infection 15.0 Alive Lung
11 Open 282 800 400 No 10 14.0 Alive Lung

Figure 1

Kaplan-Meier curves of overall survival (A) and recurrence-free survival (B) in patients with ACC with or without VTT ACC, adrenal cortical carcinoma."

1 Calissendorff J , Calissendorff F , Falhammar H . Adrenocortical cancer: Mortality, hormone secretion, proliferation and urine ste-roids: Experience from a single centre spanning three decades[J]. BMC Endocr Disord, 2016, 16, 15.
doi: 10.1186/s12902-016-0095-9
2 De Filpo G , Mannelli M , Canu L . Adrenocortical carcinoma: Current treatment options[J]. Curr Opin Oncol, 2021, 33 (1): 16- 22.
doi: 10.1097/CCO.0000000000000695
3 Brönimann S , Garstka N , Remzi M . Treatment of adrenocortical carcinoma: Oncological and endocrine outcomes[J]. Curr Opin Urol, 2023, 33 (1): 50- 58.
doi: 10.1097/MOU.0000000000001045
4 Xu WH , Wu J , Wang J , et al. Screening and identification of potential prognostic biomarkers in adrenocortical carcinoma[J]. Front Genet, 2019, 10, 821.
doi: 10.3389/fgene.2019.00821
5 邓建华, 李汉忠, 纪志刚, 等. 肾上腺皮质癌的综合治疗[J]. 北京大学学报(医学版), 2019, 51 (2): 298- 301.
6 Quinones-Baldrich W , Alktaifi A , Eilber F , et al. Inferior vena cava resection and reconstruction for retroperitoneal tumor excision[J]. J Vasc Surg, 2012, 55 (5): 1386- 1393.
doi: 10.1016/j.jvs.2011.11.054
7 Schwarzbach MH , Hormann Y , Hinz U , et al. Clinical results of surgery for retroperitoneal sarcoma with major blood vessel involvement[J]. J Vasc Surg, 2006, 44 (1): 46- 55.
doi: 10.1016/j.jvs.2006.03.001
8 Nooromid MJ , Ju MH , Havelka GE , et al. Fifteen-year expe-rience with renal cell carcinoma with associated venous tumor thrombus[J]. Surgery, 2016, 160 (4): 915- 923.
doi: 10.1016/j.surg.2016.06.029
9 Shao P , Li J , Qin C , et al. Laparoscopic radical nephrectomy and inferior vena cava thrombectomy in the treatment of renal cell carcinoma[J]. Eur Urol, 2015, 68 (1): 115- 122.
doi: 10.1016/j.eururo.2014.12.011
10 Agochukwu N , Shuch B . Clinical management of renal cell carcinoma with venous tumor thrombus[J]. World J Urol, 2014, 32 (3): 581- 589.
doi: 10.1007/s00345-014-1276-7
11 Fairweather M , Raut CP . Nephrectomy for retroperitoneal sarcoma: Stay calm and (cautiously) carry on[J]. Ann Surg Oncol, 2021, 28 (3): 1275- 1277.
doi: 10.1245/s10434-020-09293-w
12 Liu Z , Ge L , Liu L , et al. Clinical experience and management strategy of retroperitoneal tumor with venous tumor thrombus involvement[J]. Front Oncol, 2022, 12, 873729.
doi: 10.3389/fonc.2022.873729
13 Jannello LMI, Incesu RB, Morra S, et al. The European Network for the Study of Adrenal Tumors staging system (2015): A United States validation[J/OL]. J Clin Endocrinol Metab, 2024: dgae047[2024-02-18]. doi: 10.1210/clinem/dgae047.
14 Liu Z , Zhao X , Ge L , et al. Completely laparoscopic versus open radical nephrectomy and infrahepatic tumor thrombectomy: Comparison of surgical complexity and prognosis[J]. Asian J Surg, 2021, 44 (4): 641- 648.
doi: 10.1016/j.asjsur.2020.12.003
15 Zhang G , Li X , Sun G , et al. Clinical analysis of Kimura's di-sease in 24 cases from China[J]. BMC Surg, 2020, 20 (1): 1.
doi: 10.1186/s12893-019-0673-7
16 Liu Z , Li Y , Zhang Y , et al. PUTH grading system for urinary tumor with supradiaphragmatic tumor thrombus: Different surgical techniques for different tumor characteristics[J]. Front Oncol, 2022, 11, 735145.
doi: 10.3389/fonc.2021.735145
17 Blute ML , Leibovich BC , Lohse CM , et al. The Mayo clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus[J]. BJU Int, 2004, 94 (1): 33- 41.
doi: 10.1111/j.1464-410X.2004.04897.x
18 Laan DV , Thiels CA , Glasgow A , et al. Adrenocortical carcinoma with inferior vena cava tumor thrombus[J]. Surgery, 2017, 161 (1): 240- 248.
doi: 10.1016/j.surg.2016.07.040
19 Piardi T , Lhuaire M , Memeo R , et al. Laparoscopic Pringle maneuver: How we do it?[J]. Hepatobiliary Surg Nutr, 2016, 5 (4): 345- 349.
doi: 10.21037/hbsn.2015.11.01
20 Fiore M , Colombo C , Locati P , et al. Surgical technique, morbi-dity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava[J]. Ann Surg Oncol, 2012, 19 (2): 511- 518.
doi: 10.1245/s10434-011-1954-2
21 刘磊, 王国良, 马潞林, 等. 肾上腺区巨大肿瘤合并瘤栓的诊断与治疗[J]. 北京大学学报(医学版), 2019, 51 (4): 684- 688.
22 杨华安, 郭胜杰. 肾上腺皮质癌合并静脉癌栓的手术治疗及预后[J]. 实用医学杂志, 2020, 36 (10): 1344- 1348.
doi: 10.3969/j.issn.1006-5725.2020.10.015
23 Zhao X , Liu Z , Zhang H , et al. PKUTHLP score: A comprehensive system to predict surgical approach in radical nephrectomy and thrombectomy[J]. Oncol Lett, 2020, 20 (1): 201- 208.
doi: 10.3892/ol.2020.11571
24 Vuong NS , Ferriere JM , Michiels C , et al. Robot-assisted versus open surgery for radical nephrectomy with level 1-2 vena cava tumor thrombectomy: A French monocenter experience (UroCCR study #73)[J]. Minerva Urol Nephrol, 2021, 73 (4): 498- 508.
25 Treiger BF , Humphrey LS , Peterson CV , et al. Transesophageal echocardiography in renal cell carcinoma: An accurate diagnostic technique for intracaval neoplastic extension[J]. J Urol, 1991, 145 (6): 1138- 1140.
doi: 10.1016/S0022-5347(17)38556-7
[1] Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588.
[2] Kewei CHEN,Zhuo LIU,Shaohui DENG,Fan ZHANG,Jianfei YE,Guoliang WANG,Shudong ZHANG. Clinical diagnosis and treatment of renal angiomyolipoma with inferior vena cava tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 617-623.
[3] Jie YANG,Jieli FENG,Shudong ZHANG,Lulin MA,Qing ZHENG. Clinical effects of transesophageal echocardiography in different surgical methods for nephrectomy combined with Mayo Ⅲ-Ⅳ vena tumor thrombectomy [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 631-635.
[4] Binshuai WANG,Min QIU,Qianjin ZHANG,Maofeng TIAN,Lei LIU,Guoliang WANG,Min LU,Xiaojun TIAN,Shudong ZHANG. Experience in diagnosis and treatment of 6 cases of renal Ewing's sarcoma with venous thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 636-639.
[5] Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG. Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 661-666.
[6] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[7] Yangyi FANG,Qiang LI,Zhigao HUANG,Min LU,Kai HONG,Shudong ZHANG. Well-differentiated papillary mesothelial tumour of the tunica vaginalis: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 741-744.
[8] Yuanyuan ZENG,Yun XIE,Daonan CHEN,Ruilan WANG. Related factors of euthyroid sick syndrome in patients with sepsis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 526-532.
[9] Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[10] Huan-rui LIU,Xiang PENG,Sen-lin LI,Xin GOU. Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 793-801.
[11] Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811.
[12] Dong LAN,Zhuo LIU,Yu-xuan LI,Guo-liang WANG,Xiao-jun TIAN,Lu-lin MA,Shu-dong ZHANG,Hong-xian ZHANG. Risk factors for massive hemorrhage after radical nephrectomy and removal of venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 825-832.
[13] Han LU,Jian-yun ZHANG,Rong YANG,Le XU,Qing-xiang LI,Yu-xing GUO,Chuan-bin GUO. Clinical factors affecting the prognosis of lower gingival squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 702-707.
[14] Yun-fei SHI,Hao-jie WANG,Wei-ping LIU,Lan MI,Meng-ping LONG,Yan-fei LIU,Yu-mei LAI,Li-xin ZHOU,Xin-ting DIAO,Xiang-hong LI. Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 521-529.
[15] Xiao-juan ZHU,Hong ZHANG,Shuang ZHANG,Dong LI,Xin LI,Ling XU,Ting LI. Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 243-253.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd